Impact of Glycemic Control Strategies on the Progression of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial demonstrated similar long-term clinical effectiveness of insulin-sensitizing (IS) versus insulin-providing (IP) treatments for type 2 diabetes on cardiovascular outcomes in a cohort with documented coronary artery disease. We evaluated the effects of randomized glycemic control strategy (IS vs. IP) on the prevalence and incidence of diabetic peripheral neuropathy (DPN). RESEARCH DESIGN AND METHODS: DPN (defined as Michigan Neuropathy Screening Instrument [MNSI] clinical examination score >2) was assessed at baseline and yearly for 4 years. DPN prevalence and incidence were compared by intention-to-treat modeling by logistic generalized estimating equation models for prevalence and Kaplan-Meier estimates and Cox regression models for incidence rates. RESULTS: Results are reported for 2,159 BARI 2D participants (70% males) with valid baseline and at least one follow-up MNSI score (mean age 62 ± 9 years, mean HbA1c 7.7 ± 1.6%, diabetes duration 10 ± 9 years). There were no differences in the prevalence of DPN between the IS and the IP groups throughout the 4 years of follow-up. In 1,075 BARI 2D participants with no DPN at baseline, the 4-year cumulative incidence rate of DPN was significantly lower in the IS (66%) than in the IP (72%) strategy group (P = 0.02), which remained significant after adjusting for the in-trial HbA1c (P = 0.04). In subgroup analyses, IS strategy had a greater benefit in men (hazard ratio 0.75 [99% CI 0.58–0.99], P < 0.01). CONCLUSIONS: Among patients with type 2 diabetes followed for up to 4 years during BARI 2D, a glycemic control therapy with IS significantly reduced the incidence of DPN compared with IP therapy and may add further benefit for men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A combination of typical symptomatology and symmetrical distal sensory loss, or typical signs in the absence of symptoms, in a person with DM is highly suggestive of DPN and may not require additional evaluations or referral.547,565–567”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [566]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The diagnosis of DPN is principally a clinical one.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [566]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760 · cited 1×
“In addition, the weight gain observedwith the IP treatment could have contributed to an increase in chronic inflammation and oxidative stress (36).”
BackgroundTesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
The global burden of diabetic foot disease
Boulton, A. J., Vileikyte, L., Ragnarson-Tennvall, G., & Apelqvist, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67698-2 · Cited by 2,566 · cited 2×
“The 3-year survival rate in patients with DPN is 20% less than in age- and sex-matched diabetic patients without this complication (1,2).”
BackgroundA Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805796 · Cited by 1,939
Feldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293 · cited 4×
“2 was shown to have the highest sensitivity and specificity of correctly classifying DPN (11,13); therefore, in the present analysis, DPN was defined as an MNSI clinical examination score of .”
BackgroundMethodInfluentialHaffner, S. M., Greenberg, A. S., Weston, W. M., Chen, H., Williams, K., & Freed, M. I. (2002) · Circulation · doi:10.1161/01.cir.0000025403.20953.23 · Cited by 884 · cited 1×
“In this respect, experimental and human data demonstrate that TZDs may reduce inflammatory responses through NF-kB blockade (20,21).”
BackgroundEnhanced glucose control for preventing and treating diabetic neuropathy
Callaghan, B. C., Little, A. A., Feldman, E. L., & Hughes, R. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007543.pub2 · Cited by 584
Metformin Inhibits Proinflammatory Responses and Nuclear Factor-κB in Human Vascular Wall Cells
Isoda, K., Young, J. L., Zirlik, A., MacFarlane, L. A., Tsuboi, N., Gerdes, N., Schönbeck, U., & Libby, P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000201938.78044.75 · Cited by 499
Herman, W. H., Pop‐Busui, R., Braffett, B. H., Martin, C. L., Cleary, P. A., Albers, J. W., Feldman, E. L., & The DCCT/EDIC Research Group (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03644.x · Cited by 493 · cited 4×
“2 was shown to have the highest sensitivity and specificity of correctly classifying DPN (11,13); therefore, in the present analysis, DPN was defined as an MNSI clinical examination score of .”
BackgroundMethodSelf-citationAlbers, J. W., Herman, W. H., Pop-Busui, R., Feldman, E. L., Martin, C. L., Cleary, P. A., Waberski, B. H., Lachin, J. M., & for the DCCT/EDIC Research Group (2010) · Diabetes Care · doi:10.2337/dc09-1941 · Cited by 401
Self-citationNeuropathy among the diabetes control and complications trial cohort 8 years after trial completion
Martin, C. L., Albers, J., Herman, W. H., Cleary, P., Waberski, B., Greene, D. A., Stevens, M. J., & Feldman, E. L. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1549 · Cited by 350
Insulin resistance in the nervous system
Kim, B., & Feldman, E. L. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.12.004 · Cited by 321 · cited 1×
“Although not in keeping with the burden of evidence in patients with T2DM (5) and with theoretical mechanisms of benefit to peripheral nerves (34), experimental evidence suggests that the hyperinsulinemia induced by the exogenous administration of insulindand by extension, the hyperinsulinemia induced by insulin secre…”
BackgroundWile, D. J., & Toth, C. (2010) · Diabetes Care · doi:10.2337/dc09-0606 · Cited by 283
DCCT Research Group, B. N. (1995) · Annals of Neurology · doi:10.1002/ana.410380607 · Cited by 283
Doupis, J., Lyons, T. E., Wu, S., Gnardellis, C., Dinh, T., & Veves, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2385 · Cited by 266
Detaille, D., Guigas, B., Chauvin, C., Batandier, C., Fontaine, E., Wiernsperger, N., & Leverve, X. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2179 · Cited by 263
Effect of Metformin on Carbohydrate and Lipoprotein Metabolism in NIDDM Patients
Wu, M.-S., Johnston, P., Sheu, W.-H., Hollenbeck, C., Jeng, C.-Y., Goldfine, I., Chen, Y.-D., & Reaven, G. (1990) · Diabetes Care · doi:10.2337/diacare.13.1.1 · Cited by 257 · cited 1×
“Metformin also has pleiotropic actionswith direct vascular effects, such as improvement in lipid profiles (30), prevention of oxidative stress-induced endothelial cell death (31), and direct neuroprotective effects in primary neurons through inhibition of apoptotic cell death related to oxidative stress (32).”
BackgroundEl-Mir, M.-Y., Detaille, D., R-Villanueva, G., Delgado-Esteban, M., Guigas, B., Attia, S., Fontaine, E., Almeida, A., & Leverve, X. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-9002-1 · Cited by 244 · cited 1×
“Metformin also has pleiotropic actionswith direct vascular effects, such as improvement in lipid profiles (30), prevention of oxidative stress-induced endothelial cell death (31), and direct neuroprotective effects in primary neurons through inhibition of apoptotic cell death related to oxidative stress (32).”
BackgroundBeyond Hemoglobin A1c—Need for Additional Markers of Risk for Diabetic Microvascular Complications
Hirsch, I. B. (2010) · JAMA · doi:10.1001/jama.2010.785 · Cited by 184
Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway
Cameron, N., & Cotter, M. (2008) · Current Drug Targets · doi:10.2174/138945008783431718 · Cited by 179
Hur, J., Sullivan, K. A., Pande, M., Hong, Y., Sima, A. A. F., Jagadish, H. V., Kretzler, M., & Feldman, E. L. (2011) · Brain · doi:10.1093/brain/awr228 · Cited by 158
Pop‐Busui, R., Lu, J., Lopes, N., & Jones, T. L. Z. (2009) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2009.00200.x · Cited by 133
Self-citationAzad, N., Emanuele, N., Abraira, C., Henderson, W. G., Colwell, J. A., Levin, S. R., Nuttall, F. Q., Comstock, J. P., Sawin, C. T., Silbert, C. K., et al. (1999) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(99)00062-8 · Cited by 130
The Thiazolidinedione Pioglitazone Alters Mitochondrial Function in Human Neuron-Like Cells
Ghosh, S., Patel, N., Rahn, D. A., McAllister, J., Sadeghi, S., Horwitz, G., Berry, D., Wang, K. X., & Swerdlow, R. H. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.033845 · Cited by 124 · cited 1×
“For instance, TZDs may reduce oxidative stress by modulating the altered expression of reduced NADPH oxidase and by promoting improvement of mitochondrial function (24,25) independently from their glucose-lowering and IS properties.”
BackgroundMartens, F. M. A. C., Visseren, F. L. J., de Koning, E. J. P., & Rabelink, T. J. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000187176.13403.05 · Cited by 105
Hwang, J., Kleinhenz, D. J., Rupnow, H. L., Campbell, A. G., Thulé, P. M., Sutliff, R. L., & Hart, C. M. (2007) · Vascular Pharmacology · doi:10.1016/j.vph.2007.01.007 · Cited by 104
Brooks, M. M., Frye, R. L., GENUTH, S. M., Detre, K. M., Nesto, R. W., Sobel, B. E., Kelsey, S. F., & Orchard, T. J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.02.023 · Cited by 101
Self-citationWang, Y., Schmeichel, A. M., Iida, H., Schmelzer, J. D., & Low, P. A. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.03.011 · Cited by 95
Agarwal, R. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00289.2005 · Cited by 90 · cited 1×
“In this respect, experimental and human data demonstrate that TZDs may reduce inflammatory responses through NF-kB blockade (20,21).”
BackgroundYamagishi, S., Ogasawara, S., Mizukami, H., Yajima, N., Wada, R., Sugawara, A., & Yagihashi, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05050.x · Cited by 86
Sobel, B. E., Hardison, R. M., Genuth, S., Brooks, M. M., McBane, R. D., Schneider, D. J., Pratley, R. E., Huber, K., Wolk, R., Krishnaswami, A., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.014860 · Cited by 78
Self-citationHaneda, M., Koya, D., & Kikkawa, R. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.27438 · Cited by 72 · cited 1×
“TZD may also reduce generation of advanced glycation end products and may prevent the activation of protein kinase C (26,27).”
Backgroundp38 Mediates Mechanical Allodynia in a Mouse Model of Type 2 Diabetes
Cheng, H. T., Dauch, J. R., Oh, S. S., Hayes, J. M., Hong, Y., & Feldman, E. L. (2010) · Molecular Pain · doi:10.1186/1744-8069-6-28 · Cited by 62 · cited 1×
“nuclear factor-kB (NF-kB) activation (15,16) and upregulation of multiple inflammatory mediators, including tumor necrosis factor-a, in the sensory neurons from T2DM models early in the course of DPN (17).”
Rosiglitazone Treatment Reduces Diabetic Neuropathy in Streptozotocin-Treated DBA/2J Mice
Wiggin, T. D., Kretzler, M., Pennathur, S., Sullivan, K. A., Brosius, F. C., & Feldman, E. L. (2008) · Endocrinology · doi:10.1210/en.2008-0869 · Cited by 60 · cited 1×
“They were shown to slow or prevent the development of neuropathy in animal models of T1DM bymaintaining normal myelinated fiber architecture and number, reducing macrophage infiltration in the sciatic nerve, and modulating key regulatory elements in genes involved in DPN progression (28,29).”
BackgroundQiang, X., Satoh, J., Sagara, M., Fukuzawa, M., Masuda, T., Miyaguchi, S., Takahashi, K., & Toyota, T. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90354-7 · Cited by 47
Cited by
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
“DSPN may be present in at least 10%–15% of newly diagnosed patients with type 2 diabetes (44,45), with rates increasing to 50% after 10 years of disease duration (25,26).”
BackgroundMethodSelf-citationFeldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
Self-citationSelvarajah, D., Kar, D., Khunti, K., Davies, M. J., Scott, A. R., Walker, J., & Tesfaye, S. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30081-6 · Cited by 556
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationPathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Metadata
- Authors
- Pop-Busui, R., Lu, J., Brooks, M. M., Albert, S., Althouse, A. D., Escobedo, J., Green, J., Palumbo, P., Perkins, B. A., Whitehouse, F., Jones, T. L. Z., & for the BARI 2D Study Group
- Affiliations
- Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan
- University of Pittsburgh (US)
- Saint Louis University (US)
- Mexican Social Security Institute (MX)
- Duke University (US)
- Mayo Clinic (US)
- University of Toronto (CA)
- Henry Ford Health (US)
- National Institutes of Health (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-09-14
- Volume
- 36
- Issue
- 10
- Pages
- 3208-3215
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3781573
- OpenAlex
- W2126800252
- Cited by
- 167
- References
- 38
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 15 · 2023: 13 · 2022: 12 · 2021: 24 · 2020: 25 · 2019: 11 · 2018: 21 · 2017: 5 · 2016: 8 · 2015: 7 · 2014: 7
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Amylin Pharmaceuticals
- GlaxoSmithKline
- Sanofi
- Medtronic
- European Foundation for the Study of Diabetes
- Novo Nordisk
- National Institutes of Health
- National Heart, Lung, and Blood Institute (U01HL063804, U01HL061748, U01HL061744, U01HL061746)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK020572)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetic peripheral neuropathy, glycemic control, insulin sensitizers, insulin therapy, type 2 diabetes, BARI 2D trial, neuropathy incidence, neuropathy prevalence, sex differences, Michigan Neuropathy Screening Instrument, coronary artery disease
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Peripheral Nervous System Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.